New medicines from Gilead Sciences Inc., Roche Holding AG, Pharmacyclics Inc. and others are poised to reshape treatment of the most common form of leukemia among adults, potentially eliminating chemotherapy from regimens and extending patients’ lives.
Biogen Idec Inc.’s multiple sclerosis drug Tecfidera won designation as a “new active substance” in Europe, giving it added protection against generic copies and paving the way for approval there. The shares rose the most in more than two years.
Johnson & Johnson and Pharmacyclics Inc. won U.S. approval for their breakthrough therapy to treat a rare blood cancer, becoming the second drug to gain marketing clearance under the process created to speed new medicines to seriously ill patients.
Amgen Inc., the biotechnology company that completed its $10.4 billion acquisition of Onyx Pharmaceuticals Inc. this month, boosted its 2013 forecast after third-quarter earnings rose 24 percent on higher drug sales.
Ariad Pharmaceuticals Inc. tumbled the most ever after U.S. regulators placed a hold on enrollment in all trials of the company’s approved cancer drug Iclusig because of blood clots among participants.
Myriad Genetics Inc. Chief Executive Officer Pete Meldrum says his lab test to pinpoint tumors with a specific genetic mutation could have helped Sanofi-Aventis SA succeed if it had been used in a study of a drug that failed in breast cancer.
The safety of Ariad Pharmaceuticals Inc.’s leukemia drug Iclusig is being investigated by U.S. regulators because of the increasing frequency of reports of serious blood clots and narrowing of blood vessels in patients.
Myriad Genetics Inc. , the maker of genetic tests that predict breast cancer risk, rose to its highest price in five months in Nasdaq trading after an analyst upgraded the company and said it may be an acquisition target.